A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily PI & Once-Daily Non-NRTI – Containing Therapy Combinations for Initial Treatment of HIV-1 Infected individuals from Resource – Limited Settings (PEARLS) Trial
Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID)
Protocol Summary: A5175 was a phase IV, randomized, open-label, three-arm, antiviral efficacy trial designed to evaluate three antiretroviral (ARV) regimens for treatment-naïve HIV-infected participants: one regimen containing two nucleoside reverse transcriptase inhibitors (NRTIs) + a protease inhibitor (PI) and two regimens each containing two NRTIs + a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Years: 2005 – 2009
Investigator: James Hakim, MBChB, FRCP
Location: Parirenyatwa CRS